Skip to content
value.today
Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS
$65 Mmarket cap on Oct 29, 2026-69.9% since Jan 2024
Compare
World rank
#20,335
Revenue
$48 M
For year ending December-2025
Net income
$-170 M
-351.5% margin
SEC filing
Employees
—

Gossamer Bio, Inc. in brief

Gossamer Bio, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $65 M on 29 October 2026, which makes it the 20,335th largest listed company in the world and the 3,740th largest in the USA on this site. In the year to December 2025 it had sales of $48 M and a net loss of $170 M. Faheem Hasnain is its chief executive. Its largest product and service lines by sales in 2025 were Revenue from contracts with collaborators (100%). Its shares trade under the symbol GOSS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Gossamer Bio, Inc.

Gossamer Bio is a Clinical Stage Biopharmaceutical company. It is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company estimated annual revenue is currently 6 million USD per year and 118 employees as on 2020 . The headquarters is in USA.

Gossamer Bio, Inc. timeline

2 events, 2018–2019
  1. 2018
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2019
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 8 February 2019; shares registered for exchange trading on 4 February 2019.

Events of Gossamer Bio, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$253 M$506 M$759 M$1.0 B2020202120222023202420252026

World rank over time

▼ down 12,463 places since 2020
2020-01-01: #7921#7,92120202021-01-01: #9314#9,31420212022-01-07: #9969#9,96920222022-12-25: #18593#18,59320222023-07-30: #20609#20,60920232024-01-05: #17482#17,48220242026-03-08: #9760#9,76020262026-08-01: #18241#18,24120262026-10-14: #20764#20,76420262026-10-29: #20384#20,3842026

Rank in USA: #1,991 (Jan 2020) · #2,443 (Jan 2021) · #2,642 (Jan 2022) · #3,782 (Dec 2022) · #4,031 (Jul 2023) · #3,188 (Jan 2024) · #1,900 (Mar 2026) · #3,579 (Aug 2026) · #3,765 (Oct 2026) · #3,744 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.8×
Price / book
—
Free cash flow yield
-262.1%
Net margin (TTM)
-159.5%
Operating margin
-352.2%
Return on equity
—
Liabilities / assets
171.3%
Net debt
$-46M
Revenue growth
-57.7%
R&D / revenue
359.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-147M—FY18Fiscal year ending Dec 2019: revenue —, net income $-180M—FY19Fiscal year ending Dec 2020: revenue —, net income $-243M—FY20Fiscal year ending Dec 2021: revenue —, net income $-234M—FY21Fiscal year ending Dec 2022: revenue —, net income $-229M—FY22Fiscal year ending Dec 2023: revenue —, net income $-180M—FY23Fiscal year ending Dec 2024: revenue $115M, net income $-57M$115MFY24Fiscal year ending Dec 2025: revenue $48M, net income $-170M$48MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$48M-57.7%$-171M$-170M-351.5%
Dec 2024$115M—$-60M$-57M-49.3%
Dec 2023——$-184M$-180M—
Dec 2022——$-219M$-229M—
Dec 2021——$-216M$-234M—
Dec 2020——$-234M$-243M—
Dec 2019——$-186M$-180M—
Dec 2018——$-149M$-147M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-171M$0M$-171M$-0.75—
Dec 2024$-3M$0M$-3M$-0.25—
Dec 2023$-159M$0M$-159M$-1.18—
Dec 2022$-187M$0M$-187M$-2.71—
Dec 2021$-189M$2M$-190M$-3.13—
Dec 2020$-176M$2M$-178M$-3.55—
Dec 2019$-145M$3M$-148M$-3.29—
Dec 2018$-51M$3M$-55M$-22.59—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$78M
Net income, trailing 12 months
$-125M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-33M—Dec ’24Three months to Mar 2025: revenue $10M, net income $-37M$10MMar ’25Three months to Jun 2025: revenue $11M, net income $-38M$11MJun ’25Three months to Sep 2025: revenue $13M, net income $-48M$13MSep ’25Three months to Dec 2025 (from the annual report): revenue $14M, net income $-47M$14MDec ’25Three months to Mar 2026: revenue $17M, net income $-47M$17MMar ’26Three months to Jun 2026: revenue $9M, net income $17M$9MJun ’26Three months to Sep 2026: revenue $38M, net income $-48M$38MSep ’26

Latest quarter to Sep 2026: revenue $38M (+189.2% on a year earlier), net income $-48M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Gossamer Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$48 M
Operating income
$-171 M
Net income
$-170 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$172 M
Total liabilities
$295 M
Total equity
$-123 M

As of December-2025

Top 73 institutional investors in Gossamer Bio, Inc.#

As of Sep 30, 2026
73 institutions held 3.8 M shares (about 62.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 41.9%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Gossamer Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1683 Capital Management, LLC489,985New8.01%$6 MNov 16, 2026
2Opaleye Management Inc.426,989New6.98%$5 MNov 16, 2026
3Context Capital Management, LLC361,830New5.92%$4 MNov 4, 2026
4D. E. Shaw & Co., Inc.304,748New4.98%$4 MNov 16, 2026
5FMR LLC290,939New4.76%$3 MNov 10, 2026
6SummitTX Capital, L.P.182,111New2.98%$2 MNov 16, 2026
7Vanguard Capital Management LLC160,648New2.63%$2 MNov 13, 2026
8Kalehua Capital Management LLC139,366New2.28%$2 MNov 13, 2026
9BlackRock, Inc.107,423New1.76%$1 MNov 13, 2026
10ARCH Venture Management, LLC100,698New1.65%$1 MNov 16, 2026
11Marshall Wace, LLP99,503New1.63%$1 MNov 13, 2026
12Samsara Biocapital, LLC87,956New1.44%$1 MNov 16, 2026
13Corient Private Wealth LP83,160New1.36%$1 MNov 16, 2026
14Highbridge Capital Management LLC75,697New1.24%$1 MNov 16, 2026
15Geode Capital Management, LLC70,318New1.15%$1 MNov 6, 2026
16Siren, L.L.C.65,112New1.06%$1 MNov 12, 2026
17Squarepoint Ops LLC64,853New1.06%$1 MNov 9, 2026
18Stonepine Capital Management, LLC63,039New1.03%$1 MNov 13, 2026
19Hhlr Advisors, LTD.62,175New1.02%$1 MNov 16, 2026
20Bank Of America Corp /de/60,383New0.99%$1 MNov 16, 2026
21Balyasny Asset Management L.P.45,540New0.74%$1 MNov 16, 2026
22Arrowstreet Capital, Limited Partnership41,604New0.68%$0 MNov 13, 2026
23Jane Street Group, LLC37,652New0.62%$0 MNov 12, 2026
24Vanguard Fiduciary Trust Co35,683New0.58%$0 MNov 13, 2026
25Gsa Capital Partners LLP32,806New0.54%$0 MNov 16, 2026
Show all 73: investors 26 to 73
Institutional investors 26 to 73 in Gossamer Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26State Street Corp32,175New0.53%$0 MNov 12, 2026
27MB Generational Wealth, LLC27,904New0.46%$0 MNov 9, 2026
28Renaissance Technologies LLC27,725New0.45%$0 MNov 12, 2026
29Monaco Asset Management SAM25,461New0.42%$0 MNov 9, 2026
30Empery Asset Management, LP24,954New0.41%$0 MNov 16, 2026
31Goldman Sachs Group Inc24,826New0.41%$0 MNov 16, 2026
32Ishara Investments LP24,000New0.39%$0 MNov 16, 2026
33Luminus Management LLC19,611New0.32%$0 MNov 16, 2026
34Ensign Peak Advisors, Inc16,751New0.27%$0 MNov 12, 2026
35Vanguard Portfolio Management LLC16,500New0.27%$0 MNov 13, 2026
36UBS Group AG14,984New0.24%$0 MNov 10, 2026
37Hennion & Walsh Asset Management, Inc.14,203New0.23%$0 MOct 13, 2026
38AQR Capital Management LLC13,974New0.23%$0 MNov 16, 2026
39Northern Trust Corp13,940New0.23%$0 MNov 16, 2026
40Invesco Ltd.13,054New0.21%$0 MNov 12, 2026
41Smith, Moore & Co.11,250New0.18%$0 MNov 12, 2026
42Morgan Stanley6,763New0.11%$0 MNov 13, 2026
43Citigroup Inc5,250New0.09%$0 MNov 4, 2026
44Acadian Asset Management LLC4,468New0.07%$0 MNov 9, 2026
45Quarry LP3,000New0.05%$0 MNov 16, 2026
46Deutsche Bank AG\1,831New0.03%$0 MNov 6, 2026
47Osaic Holdings, Inc.1,626New0.03%$0 MNov 12, 2026
48Group One Trading LLC1,421New0.02%$0 MNov 10, 2026
49Tower Research Capital LLC (TRC)1,337New0.02%$0 MNov 16, 2026
50Rockefeller Capital Management L.P.1,320New0.02%$0 MNov 13, 2026
51China Universal Asset Management Co., Ltd.1,115New0.02%$0 MOct 28, 2026
52Vanguard Global Advisers, LLC996New0.02%$0 MNov 13, 2026
53Farther Finance Advisors, LLC641New0.01%$0 MOct 8, 2026
54Federation des caisses Desjardins du Quebec609New0.01%$0 MNov 16, 2026
55Russell Investments Group, Ltd.455New0.01%$0 MNov 6, 2026
56BNP Paribas Financial Markets349New0.01%$0 MNov 12, 2026
57Royal Bank Of Canada318New0.01%$0 MNov 16, 2026
58Mirae Asset Global Investments Co., Ltd.312New0.01%$0 MOct 29, 2026
59Clearstead Advisors, LLC294New0.00%$0 MNov 6, 2026
60Jpmorgan Chase & Co287New0.00%$0 MNov 12, 2026
61Rialto Wealth Management, LLC256New0.00%$0 MNov 16, 2026
62Robinhood Markets, Inc.107—0.00%$0 MNov 18, 2026
63BFC Planning, Inc.78New0.00%$0 MNov 13, 2026
64Jones Financial Companies Lllp55New0.00%$0 MNov 13, 2026
65GAMMA Investing LLC44New0.00%$0 MOct 8, 2026
66Essential Partners LLC32New0.00%$0 MOct 14, 2026
67Planning Strategies Inc.32New0.00%$0 MOct 2, 2026
68EverSource Wealth Advisors, LLC31New0.00%$0 MNov 4, 2026
69Parallel Advisors, LLC26New0.00%$0 MNov 3, 2026
70Nisa Investment Advisors, LLC24New0.00%$0 MOct 20, 2026
71Arax Advisory Partners17New0.00%$0 MNov 12, 2026
72Wells Fargo & Company/mn12New0.00%$0 MNov 16, 2026
73SBI Securities Co., Ltd.4New0.00%$0 MOct 22, 2026

Mutual funds holding Gossamer Bio, Inc.#

44 funds hold shares worth $3 M (about 4.1% of the company). Since their previous reports 15 added shares and 59 sold, selling $4 M net.
Mutual funds holding Gossamer Bio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.6.91 M$1 M1.6%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.2.24 M$0 M0.51%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC1.15 M$0 M0.26%<0.01%+6.1%May 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors1.50 M$0 M0.34%<0.01%−0.6%Jun 30, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.986,826$0 M0.22%<0.01%−1.6%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.977,030$0 M0.22%<0.01%+2.8%May 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.541,950$0 M0.12%<0.01%−0.9%May 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC556,395$0 M0.13%<0.01%+17%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC381,135$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC365,199$0 M0.08%<0.01%no changeMay 29, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC300,421$0 M0.07%<0.01%+1.6%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors294,007$0 M0.07%<0.01%+2.5%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.267,245$0 M0.06%<0.01%+1046%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.180,256$0 M0.04%<0.01%+3.1%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC149,688$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.154,416$0 M0.03%<0.01%+24%Jun 30, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC145,404$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.107,368$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company73,097$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC99,976$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC57,126$0 M0.01%<0.01%+86%May 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC74,746$0 M0.02%<0.01%+16%Jul 31, 2026
🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION47,330$0 M0.01%<0.01%+108%May 31, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC60,195$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC59,400$0 M0.01%<0.01%+40%Jun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors50,820$0 M0.01%<0.01%−22%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION28,300$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC35,839$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC36,524$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC31,955$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC30,015$0 M<0.01%<0.01%−18%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.16,683$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC21,834$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC13,387$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC9,043$0 M<0.01%<0.01%+8.7%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC7,222$0 M<0.01%<0.01%−5.1%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC7,146$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC10,553$0 M<0.01%<0.01%−35%Jun 30, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC7,072$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC9,057$0 M<0.01%<0.01%−7.6%Jun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC6,117$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC4,901$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC5,067$0 M<0.01%<0.01%+35%Jun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC1,290$0 M<0.01%<0.01%+7.4%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 44 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Gossamer Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
18
since
$323 K-$40 K$0Nov 2023: bought $137 K (2 trades), sold $0 (0 trades)Nov 23Mar 2024: bought $0 (0 trades), sold $40 K (5 trades)MarJun 2024: bought $323 K (3 trades), sold $1 K (1 trades)JunAug 2025: bought $50 K (1 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Gossamer Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Waage ChristianEVP, Tech Ops and AdminGrant or award+84,500——814,061Form 4
filed Faheem HasnainPresident & CEO, DirectorGrant or award+280,000——837,793Form 4
filed Caryn PetersonEVP, Regulatory AffairsGrant or award+84,500——259,333Form 4
filed Bryan GiraudoCOO/CFOGrant or award+115,750——389,737Form 4
filed Richard ArandaChief Medical OfficerGrant or award+93,750——463,106Form 4
filed Robert Paul Smith Jr.Chief Commercial OfficerGrant or award+93,750——260,898Form 4
filed Waage ChristianEVP, Tech Ops and AdminGrant or award+125,000——710,934Form 4
filed Robert Paul Smith Jr.Chief Commercial OfficerGrant or award+162,500——162,500Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Gossamer Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.3 M
7.52 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-80 reverse split ; 1-for-454.55 reverse split

Trading halts

  • 2026-09-10 23:50 UTC, code T3, resumed 13:00 UTC
  • 2026-02-23 12:58 UTC, code T3, resumed 13:30 UTC

Fails to deliver

  • : 7,524 shares at $10.69
  • : 6,808 shares at $9.77
  • : 678 shares at $9.15
  • : 9,232 shares at $9.61
  • : 3,807 shares at $9.46

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Gossamer Bio, Inc. scorecard#

Passes 4 of the 14 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median0.8×Price to sales 0.8× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 3
    • ✗Revenue grew in the newest year-57.7%Revenue down 57.7% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.75 vs -0.25Diluted EPS -0.75 in fiscal 2025 against -0.25 the year before (report's currency).
    • ✓Net income higher than five years earlier-$170 M-$170 M in fiscal 2025 against -$243 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$170 MNet income -$170 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-352.2%-352.2% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.64 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-13.83Z-score -13.83 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.0%Diluted shares up 1.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Gossamer Bio, Inc.'s statements, beside the median of Biotechnology.

Gossamer Bio, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-352.2%-60.5%
Net margin-351.5%-68.9%
Revenue growth-57.7%15.8%
Free cash flow margin-353.5%-61.5%

1of 7on the Piotroski tests of financial strength

  • Revenue fell 57.7% against the year before.
  • Net loss of $170 million, the 9th loss-making year in a row.
  • Free cash flow was negative: -$171 million.
  • Shareholders' equity is negative: -$123 million.

Gossamer Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Gossamer Bio, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017
Income statement
Revenue4811500—————
Research and development174138135171170161143550.9
General and administrative38363848465039440.3
Operating expenses2191751842192162341861496.7
Operating income−171−60−184−219−216−234−186−149−6.7
Interest and finance income2.01.82.01.60.83.45.61.7—
Interest expense and finance costs1112141419131.90.0—
Other non-operating income (expense)0.34.33.9−11r−18r−0.25.82.0−0.1
Income before tax−170−56−180r−229r−234−243−180r−147r6.8
Income tax−0.10.900——000
Net income including minority interests−170−57−180−229−234−243−180−147−6.8
Net income attributable to shareholders−170−57−180−229−234−243−180−147−6.8
Earnings per share, basic-0.75-0.25-1.18-2.71-3.13-3.55-3.29-22.59-0.74
Earnings per share, diluted-0.75-0.25-1.18-2.71-3.13-3.55-3.29-22.59-0.74
Shares, weighted average (basic)22922615385756955——
Shares, weighted average (diluted)229226153857569556.59.2
Balance sheet
Cash and cash equivalents384632112183486135r1050.3
Short-term investments9924826414414227267123—
Receivables125.30——————
Other current assets1810106.26.59.17.53.1—
Current assets168310307262332522409232—
Property, plant and equipment0.10.01.64.05.35.55.43.2—
Right-of-use (leased) assets4.15.13.15.95.51110——
Total assets172315312272344539427239—
Accounts payable6.02.35.51.53.27.51.02.2—
Debt due within a year—012120————
Current liabilities6345524940393720—
Long-term debt—00.812292928——
Lease liabilities (non-current)3.54.40.13.43.27.78.7——
Total liabilities2952862492602222197421—
Retained earnings−1,439−1,269−1,212−1,032−812−578−334−154—
Shareholders' equity−123296312121321352−120−6.9
Total liabilities and equity172315312272344539427239—
Shares outstanding2.9r227225947674628.1—
Cash-flow statement
Depreciation and amortization0.00.81.61.81.71.40.90.3—
Share-based compensation11212943323921310.0
Cash from operating activities−171−3.5−159−187−189−176−145−51−5.7
Capital expenditure−0.100−0.4−1.5−1.5−3.0−3.5—
Cash from investing activities15629−111−1.0−117215−147−145—
Debt issued——————28——
Debt repaid0−13−12−5.800———
Shares issued———001172910—
Cash from financing activities6.4−111901173.33133223016.0
Change in cash−8.314−80−71−30335230r1050.3
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Gossamer Bio, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Revenue from contracts with collaborators$48 M100%

Business segments

  • Reporting$48 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Gossamer Bio, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.

Gossamer Bio, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries—
🇮🇪 Ireland2 subsidiaries—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Gossamer Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 4 · Material agreement 4 · Agreement ended 2 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 5 · Shareholder vote 4 · Results announced 9

Gossamer Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Bylaws or fiscal year changed8-K
Bylaws or fiscal year changed8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Results announced8-K
Material agreementAgreement endedResults announced8-K
Directors and officersBylaws or fiscal year changedShareholder vote8-K
Shareholder vote8-K
Material agreementAgreement endedNew debtUnregistered share sale8-K
Directors and officersMaterial agreementResults announced8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Unregistered share sale8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Gossamer Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$25 MPrivate placement after listing$10 to $50 million38optionsSEC
Jul 2023$212 MPrivate placement after listing$50 to $250 million70equity, optionsSEC
Jul 2022$120 MPrivate placement after listing$50 to $250 million23equitySEC
Jul 2018$230 MNo. 2$50 to $250 million67equitySEC
Jan 2018$70 MNo. 1$50 to $250 million3equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Gossamer Bio, Inc.#

$10 K spent on lobbying the US Congress and federal agencies in 2026, most often on health issues.

Lobbying, 2026
$10 K
#1,453 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2026
2026 so far
$10 K
  • Health Issues1 report

Lobbying firms hired in 2026

JEFFREY J. KIMBELL & ASSOCIATES, INC. $10 K

Gossamer Bio, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$10 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Gossamer Bio, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Gossamer Bio, Inc.#

2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $185 K a year.

Certified, FY2025
2
#1,601 among companies on value.today
Worker positions
2
Median wage offered
$185 K
a year, full-time
Applications filed
2
Gossamer Bio, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Director, Clinical Quality AssuranceMedical and Health Services Managers1$223 K
Manager, Statistical ProgrammingSoftware Developers1$148 K

Where: Billerica, MA 1 · Secaucus, NJ 1

Gossamer Bio, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202522$185 K2
FY202422$159 K2
FY202311$165 K1
FY202144$133 K4

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Gossamer Bio Services, Inc.

Layoffs at Gossamer Bio, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
65
1 notices and filings
People, all years
65
2026–2026
Latest
65 people
2026-03-16
Gossamer Bio, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026··65········65
Gossamer Bio, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
effective 65 peopleLayoffWARN noticeSan Diego, CaliforniaNotice list

Source: State WARN notices and SEC 8-K item 2.05

How Gossamer Bio, Inc. compares in Biotechnology

  • Market cap$65 M · higher than 30% of 726
  • Revenue$48 M · higher than 59% of 647
  • Net margin-159.5% · higher than 34% of 408
  • Revenue growth-57.7% · higher than 15% of 438
  • Price / sales0.8× · lower than 95% of 339

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Gossamer Bio, Inc.🇺🇸$65 M—-159.5%-57.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Gossamer Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Gossamer Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Gossamer Bio, Inc.? Suggest a correction